Tandem Diabetes Care Enters Material Definitive Agreement

TL;DR

Tandem Diabetes Care signed a big deal on 5/22. Details TBD.

AI Summary

On May 22, 2024, Tandem Diabetes Care, Inc. entered into a material definitive agreement. The filing does not disclose specific details of the agreement, such as the counterparty or the financial terms, but it is categorized under 'Entry into a Material Definitive Agreement'.

Why It Matters

This filing indicates a significant new contract or partnership for Tandem Diabetes Care, which could impact its future business operations and financial performance.

Risk Assessment

Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and impact of the agreement.

Key Players & Entities

• Tandem Diabetes Care, Inc. (company) — Registrant
• May 22, 2024 (date) — Date of earliest event reported
• 001-36189 (other) — Commission File Number
• 20-4327508 (other) — I.R.S. Employer Identification No.
• 12400 High Bluff Drive (address) — Principal executive offices
• San Diego (location) — City of principal executive offices
• California (location) — State of principal executive offices
• 92130 (zip_code) — Zip code of principal executive offices
• ( 858 ) 366-6900 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.001 — ich Registered Common Stock, par value $0.001 per share TNDM NASDAQ Global Market I

Filing Documents

• tndm-20240522.htm (8-K) — 23KB
• 0001438133-24-000158.txt ( ) — 143KB
• tndm-20240522.xsd (EX-101.SCH) — 2KB
• tndm-20240522_lab.xml (EX-101.LAB) — 21KB
• tndm-20240522_pre.xml (EX-101.PRE) — 12KB
• tndm-20240522_htm.xml (XML) — 3KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On May 22, 2024, Tandem Diabetes Care, Inc., a Delaware corporation (the "Company") and Dexcom, Inc., a Delaware corporation ("Dexcom") entered into an Amended and Restated Development Agreement to the Original Development Agreement, dated as of November 20, 2020, between the Company and Dexcom, under which the integration of the Company's insulin pumps with Dexcom's Continuous Glucose Monitoring ("CGM") devices are addressed. The Amended and Restated Development Agreement incorporates the integration of the Company's Sigi insulin pump with Dexcom's G7 CGM device, extends the term for a period of five years, and amends certain definitions and terms and conditions related to devices and development generally. On May 22, 2024, the Company and Dexcom also entered into an Amended and Restated Commercialization Agreement to the Original Commercialization Agreement, dated as of November 20, 2020, between the Company and Dexcom, under which the commercialization of the integrated solutions developed under the Amended and Restated Development Agreement are addressed. The Amended and Restated Commercialization Agreement incorporates the commercialization of the Company's Sigi insulin pump with Dexcom's G7 CGM device, extends the term for a period of five years, and amends certain definitions and terms and conditions related to devices and commercialization generally. The Company intends to file both the Amended and Restated Development Agreement and the Amended and Restated Commercialization Agreement as exhibits to the Company's Quarterly Report on Form 10-Q for the period ending June 30, 2024. 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Tandem Diabetes Care, Inc. By: /s/ SHANNON M. HANSEN Shannon M. Hansen Executive Vice President, Chief Legal, Privacy & Compliance Officer and Secretary Date: June 18, 2024 3

View Full Filing

View this 8-K filing on SEC EDGAR